Mannkind Corporation (NASDAQ:MNKD) shares traded down -0.61% during most recent session. The firm saw a rise in short interest between September 29, 2017 and October 13, 2017 of 11.26%. Based on an average daily volume of 27,541,901 shares, the days-to-cover ratio is now 1.0 days. Approximately 40.9% of the shares of the stock are short sold.
A number of equities analysts recently weighed in on the company.
November 8 investment analysts at HC Wainwright left the company rating at "Buy" with a current price target of $7.00.
Maxim Group "Downgrades" Mannkind Corporation (NASDAQ:MNKD) in a research note issued to investors on 11/01/17 to Hold with price target of $0. Now shares of Mannkind Corporation (NASDAQ:MNKD) have an average brokerage recommendation (ABR) of 2 number of Recs in ABR is 2 however the company's industry rank by ABR is out of 265.
Among 7 analysts covering Mannkind (NASDAQ:MNKD), 2 have Buy rating, 3 Sell and 2 Hold. MannKind Corporation earned a news impact score of 0.16 on Accern's scale. It has a market cap of $371.04 Million. The stock was bought at an average cost of $6.00 per share, for a total transaction of $999,600.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.
According to Finviz reported data, The SMA20 of the stock is at -12.69 percent, SMA50 is 1.82 percent, while SMA200 is 61.05 percent.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. The company net profit margin is and gross profit margin is. Wells Fargo & Company MN now owns 89,951 shares of the biopharmaceutical company's stock valued at $196,000 after purchasing an additional 30,589 shares in the last quarter.
MannKind Corporation (NASDAQ:MNKD) last released its quarterly earnings results on Monday, August 7th. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of MannKind Corporation by 20.1% in the 2nd quarter.
For the Current Quarter, the growth estimate for MannKind Corp.is -137.5%, while for the Next Quarter the stock growth estimate is -52.9%. The stock remained 1.81% unpredictable for the week and 1.83% for the month.
Mannkind Corporation (NASDAQ:MNKD) is at $3.16 with a low of $3.10 and high of $3.28. Further, company shares have been seen trading -53.88% off of the 52 week high and 381.84% away from the 52 week low. Its book value per share for the most recent quarter is $-2.4 while its price to book ratio for the same period is 0, as for as the company's cash per share for the most recent quarter is $0.17, however its price to cash per share ratio for the same period is 18.46. MannKind Corporation has a twelve month low of $0.67 and a twelve month high of $6.96.
Analysts expect MannKind Corporation (NASDAQ:MNKD) to report $-0.29 EPS on March, 15.They anticipate $0.10 EPS change or 52.63 % from last quarter's $-0.19 EPS. The Return on Equity ratio of MannKind Corp. The business had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.56 million. KCG Holdings Inc. now owns 147,952 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 107,752 shares in the last quarter. A buy rating from an analyst or research firm is a recommendation to purchase the security, with the implied insistence that the security is undervalued in some fashion.
TRADEMARK VIOLATION WARNING: "Short Interest in MannKind Corporation (MNKD) Increases By 11.3%" was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another publication, it was illegally stolen and republished in violation of USA & worldwide copyright legislation.
MannKind Corporation a US based Company, belongs to Healthcare sector and Biotechnology industry. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes.